BQCIS

Advanced Testing Solutions for Complex Biologic Products

Biotechnology products—biologics, biosimilars, and ATMPs—are complex entities requiring specialized analytical approaches. Testing must confirm structure, biological activity, purity, and safety per **ICH Q5** and pharmacopeial requirements.

BQCIS laboratories provide comprehensive physicochemical, bioassay, and microbiological testing using high-resolution analytical platforms. Our validated methods ensure critical quality attributes remain consistent across manufacturing batches and product lifecycle.

We support global submissions with validated data packages for vaccines, monoclonal antibodies, and recombinant proteins—ensuring each biologic meets the highest standards of identity, potency, and safety.

Key Biotechnology Testing Services

Physicochemical & Structural Characterization

Characterization via MS, Peptide Mapping, SEC, and Circular Dichroism to confirm molecular structure and detect aggregation. Quantification of glycosylation and post-translational modifications ensures product consistency and comparability.

Bioassay, Potency & Viral Safety Testing

Cell-based potency assays evaluate functional biological activity, while **ICH Q5A viral-safety testing** confirms absence of adventitious agents and validates viral clearance, safeguarding patient safety and regulatory compliance.

Key Benefits of Biotechnology Testing

Reliability

Scientific Reliability

Validated analytical and biological methods deliver data integrity essential for biologic approval submissions.

Speed

Accelerated Development

Integrated testing workflows streamline comparability and stability studies, reducing development timelines.

Compliance

Regulatory Confidence

Data packages aligned with ICH Q5 and pharmacopoeial guidance ensure rapid global regulatory acceptance.

Safety

Enhanced Patient Safety

Rigorous bioassay validation and viral-safety testing protect patient well-being across the therapeutic lifecycle.

Success Story

Validated Potency Assay Enables Biosimilar Market Entry

The Challenge:

A biosimilar developer required a validated potency assay to demonstrate equivalent efficacy to a reference monoclonal antibody.

Our Solution:

BQCIS designed and validated a custom ICH Q2-compliant bioassay assessing linearity, accuracy, and precision—meeting global regulatory expectations.

The Result:

The validated assay supported a successful comparability submission, enabling Phase III clinical advancement without regulatory delay.

View More Case Studies →